Adults 18 to 65, male only, with Methamphetamine Abuse or HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Methamphetamine UsePrimary· from baseline to 9-months post randomization
Days of participant self-reported methamphetamine use in the past 30 days.
Baseline
Group
Value
95% CI
Immediate Delivery (ID)
13.6
± 11.3
Delayed Delivery (DD)
15.3
± 11.2
1 month
Group
Value
95% CI
Immediate Delivery (ID)
10.9
± 10.3
Delayed Delivery (DD)
14.5
± 11.8
2 months
Group
Value
95% CI
Delayed Delivery (DD)
14.4
± 10.7
3 months
Group
Value
95% CI
Immediate Delivery (ID)
9.4
± 10.0
Delayed Delivery (DD)
13.4
± 11.6
6 months
Group
Value
95% CI
Immediate Delivery (ID)
10.2
± 10.7
Delayed Delivery (DD)
13.2
± 11.6
9 months
Group
Value
95% CI
Immediate Delivery (ID)
8.8
± 9.6
Delayed Delivery (DD)
11.7
± 11.5
Methamphetamine InjectionPrimary· From baseline to 9-months post randomization
Days participants self-reported methamphetamine injection use in past 30 days
Baseline
Group
Value
95% CI
Immediate Delivery (ID)
2.2
± 5.5
Delayed Delivery (DD)
2.3
± 5.9
1 month
Group
Value
95% CI
Immediate Delivery (ID)
1.2
± 4.4
Delayed Delivery (DD)
2.3
± 5.8
2 months
Group
Value
95% CI
Delayed Delivery (DD)
2.4
± 6.1
3 months
Group
Value
95% CI
Immediate Delivery (ID)
0.7
± 2.8
Delayed Delivery (DD)
1.6
± 4.6
6 months
Group
Value
95% CI
Immediate Delivery (ID)
1.3
± 4.7
Delayed Delivery (DD)
1.6
± 5.4
9 months
Group
Value
95% CI
Immediate Delivery (ID)
0.8
± 2.9
Delayed Delivery (DD)
0.8
± 3.4
Condomless Anal IntercoursePrimary· baseline to 9-months post randomization
Reporting condomless anal intercourse in the past 30 days (yes/no)
Baseline
Group
Value
95% CI
Immediate Delivery (ID)
63
Delayed Delivery (DD)
54
1 month
Group
Value
95% CI
Immediate Delivery (ID)
40
Delayed Delivery (DD)
55
2 months
Group
Value
95% CI
Delayed Delivery (DD)
36
3 months
Group
Value
95% CI
Immediate Delivery (ID)
32
Delayed Delivery (DD)
36
6 months
Group
Value
95% CI
Immediate Delivery (ID)
38
Delayed Delivery (DD)
35
9 months
Group
Value
95% CI
Immediate Delivery (ID)
40
Delayed Delivery (DD)
32
Condomless Anal Intercourse While High on MethamphetaminePrimary· 9-months post randomization
Reporting condomless anal intercourse while high on methamphetamine in the past 30 days (yes/no)
Baseline
Group
Value
95% CI
Immediate Delivery (ID)
56
Delayed Delivery (DD)
49
1 month
Group
Value
95% CI
Immediate Delivery (ID)
30
Delayed Delivery (DD)
42
2 months
Group
Value
95% CI
Delayed Delivery (DD)
30
3 months
Group
Value
95% CI
Immediate Delivery (ID)
26
Delayed Delivery (DD)
32
6 months
Group
Value
95% CI
Immediate Delivery (ID)
26
Delayed Delivery (DD)
28
9 months
Group
Value
95% CI
Immediate Delivery (ID)
26
Delayed Delivery (DD)
23
ART InitiationSecondary· 9-months post randomization
Starting to receive ART among HIV sero-positive participants who were not on ART at baseline (yes/no)
Group
Value
95% CI
Immediate Delivery (ID)
2
Delayed Delivery (DD)
5
PrEP InitiationSecondary· 9-months post randomization
Starting to receive PrEP among HIV sero-negative participants who were not on PrEP at baseline (Yes/No)
Group
Value
95% CI
Immediate Delivery (ID)
4
Delayed Delivery (DD)
7
Sponsor's own description
A commonly used manualized outpatient methamphetamine intervention for gay and bisexual men, "Getting Off," is being translated into a mobile phone application (i.e., app) available for download through common app marketplaces. The application will provide games, guided lessons, informational support, and resources to gay and bisexual men seeking to reduce their methamphetamine use and risky sexual behaviors.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06721494 — A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamin
· Phase 2
· recruiting
NCT06496750 — Ketamine for Methamphetamine Use Disorder
· Phase 2
· recruiting
NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder
· NA
· recruiting
NCT06233799 — Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
· Phase 3
· recruiting
NCT05700994 — Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
· NA
· active not recruiting
Other Friends Research Institute, Inc. trials
Trials by the same sponsor.
NCT07262190 — NavSTAR Implementation Effectiveness Trial Across a Health System
· NA
· recruiting
NCT06306443 — Buprenorphine for Individuals in Jail
· Phase 3
· recruiting
NCT06573476 — Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform
· NA
· recruiting
NCT07524738 — Telemedicine XR-B for Individuals in Jail
· Phase 3
· active not recruiting
NCT06569667 — Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Friends Research Institute, Inc.
Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03884946.